Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | BTK | Q06187 | 6/20 | 0.44 |
| ▸ | STK16 | O75716 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 13/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 5/20 | 0.43 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14078366 | 0.93 | JAK3 (0.59) | JAK3JAK2BTKSTK16FYN | |
| SCHEMBL1679299 | 0.92 | JAK3 (0.61) | JAK3JAK2BTKSTK16FYN | |
| SCHEMBL14234663 | 0.86 | JAK3 (0.65) | JAK3JAK2BTKSTK16FYN | |
| SCHEMBL14078354 | 0.86 | JAK3 (0.69) | JAK3JAK2BTKSTK16FYN | |
| SCHEMBL12807646 | 0.85 | JAK3 (0.63) | JAK3JAK2BTKSTK16FYN | |
| SCHEMBL1678692 | 0.85 | JAK3 (0.65) | JAK3JAK2BTKSTK16FYN | |
| SCHEMBL12807471 | 0.85 | JAK3 (0.67) | JAK3JAK2BTKSTK16FYN | |
| SCHEMBL1679418 | 0.83 | JAK3 (0.72) | JAK3JAK2BTKSTK16FYN | |
| SCHEMBL12807542 | 0.83 | JAK3 (0.62) | JAK3JAK2BTKSTK16FYN | |
| SCHEMBL12807502 | 0.82 | JAK3 (0.65) | JAK3JAK2BTKSTK16FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329737-B2 | Benzimidazoles as selective kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-12-11 | — | — | US | disclosed |
| US-8329737-B2 | Benzimidazoles as selective kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-12-11 | — | — | US | disclosed |
| EP-1704145-B1 | SELECTIVE KINASE INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2012-06-13 | — | — | EP | disclosed |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-04-07 | — | — | US | disclosed |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-04-07 | — | — | US | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | LCK, CHUK, CSK | JAK3 47/4885JAK2 51/4885BTK 7/4885 |
| US-20080207613-A1 | Selective Kinase Inhibitors | LCK, CHUK, CSK | JAK3 47/4885JAK2 51/4885BTK 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.